Lymphatic system

BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA

Retrieved on: 
Thursday, January 19, 2023
Biotechnology, Pharmaceutical, Health, Oncology, National Institute for Health and Care Excellence, MHRA, Union, Lymphatic system, Healthcare Improvement Scotland, BTK, Rituximab, NICE, CLL, SSE, SEQUOIA, Health care, Chronic lymphocytic leukemia, Patient, Physician, Medication, Pharmaceutical industry, BeiGene, Hematology

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for BRUKINSA (zanubrutinib) in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia (CLL) and the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.

Key Points: 
  • BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for BRUKINSA (zanubrutinib) in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia (CLL) and the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
  • “BRUKINSA is a highly selective BTK inhibitor that has demonstrated clinically meaningful improvements over the first generation of BTK inhibitor in relapsed CLL,” said Dr Renata Walewska, Department of Hematology, University Hospitals Dorset, Bournemouth, UK.
  • The MHRA authorization for MZL is based on results from the multicenter, global, single-arm, open-label, Phase 2 MAGNOLIA3 trial in patients with R/R MZL who received at least one anti-CD-20 based regimen.
  • BRUKINSA has also been recommended by the Scottish Medicines Consortium for the treatment of adult patients with WM who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemoimmunotherapy.

Global Cell Harvester Market Report to 2028 - Featuring Esco Micro, Sartorius, Cox Scientific and Pall Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Biotechnology, Genetics, Health, Hypertension, Degenerative disease, Burn, Growth, Application, Lymphatic system, Prevalence, Diabetes, Automation, Transplant, Investment, Regenerative medicine, Cell, Fine chemical, Forecast

The global cell harvester market is expected to witness significant growth during the forecast period, 2024-2028.

Key Points: 
  • The global cell harvester market is expected to witness significant growth during the forecast period, 2024-2028.
  • The rising organ transplantation procedure rate along with improving healthcare expenditure is anticipated to augment the growth of the global cell harvester market.
  • With thriving biotechnology and biopharmaceutical industry, the global cell harvester market is expected to grow significantly in the coming years.
  • The region is further expected to dominate the global cell harvester market through 2028 as it is witnessing increasing expenditure on healthcare sector.

Stem Cell Therapy Global Market Report 2022: Increasing Prevalence of Various Diseases Drives Demand - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
Health, Stem Cells, Degenerative disease, Cell, Tissue, Regeneration, B cell, Government, Toxic shock syndrome, T cell, Lymphatic system, Growth, Application, Patient, Prevalence, Research, Cancer, Transplant, GVHD, Stem cell, Fine chemical, Pharmaceutical industry

The "Stem cell therapy Market By Cell Source, By Application, By Type: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stem cell therapy Market By Cell Source, By Application, By Type: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • Stem cell therapy is a promising strategy for regeneration of damaged organs, tissues or functions through the transplantation of stem cells.
  • The global stem cell therapy market is anticipated to show significant market growth during the forecast period, owing to increase in demand for stem cell therapy, increase in government support for R&D activities and increase in healthcare expenditure.
  • Conversely, surge in the applications of induced pluripotent stem cells in embryonic stem cell therapy offers the lucrative opportunities for the growth of the market.

Global and Regional Molecular Oncology Diagnostics Market Report 2022: Analysis and Forecasts, 2021-2032 - Launch of Innovative Products in Molecular Oncology Diagnostics Ecosystem - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Health, General Health, Hospital, QIAGEN, Name, Agilent Technologies, Cancer, CRC, Library, Lymphatic system, Esophageal cancer, NGS, Colorectal cancer, Laboratory, Becton, Breast, Region, Bio-Rad Laboratories, Liquid biopsy, B-cell lymphoma, Polymerase chain reaction, BD, Diagnosis, Growth, PCR, Patient, Prevalence, Helmy Eltoukhy, Software, Incidence, Breast cancer, S.A, Medical imaging, Vaccine, Medical device

The growth in the global molecular oncology diagnostics market is expected to be driven by the rising prevalence of cancers and increased transformations in biomarker identification.

Key Points: 
  • The growth in the global molecular oncology diagnostics market is expected to be driven by the rising prevalence of cancers and increased transformations in biomarker identification.
  • The rising global cancer incidence and the growing demand for early detection are expected to drive the growth of the global molecular oncology diagnostics market during the forecast period.
  • The presence of major kit and assay providers of molecular oncology diagnostics has a major impact on the market.
  • Based on products, the global molecular oncology diagnostics market is expected to be dominated by kit and assay.

Asia Pacific Cell & Gene Research Growing 50% Faster than ROW

Retrieved on: 
Friday, February 3, 2023
AU, Degenerative disease, Gene, ROW, The Sporting News Minor League Player of the Year Award, Lymphatic system, Cros, CNS, Infection, Patent, Research, Acquisition, European, Investment, Cell, Fine chemical, Agriculture

SYDNEY, AU, Feb 3, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW.

Key Points: 
  • SYDNEY, AU, Feb 3, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW.
  • Novotech, which has extensive experience in cell & gene therapy clinical trials, is sponsoring the 6th Annual Cell And Gene Therapy Innovation Summit in Berlin, Germany (15-16 February 2023).
  • The latest data shows Asia Pacific is the fastest-growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies, with China leading in the region.
  • The region already accounts for over a third of cell & gene therapy trial activity and shows a nearly 50% faster growth rate in cell & gene therapy trials compared to ROW between 2016 and 2021.

Healthcare Industry Leaders and Workplace Equity Champions Announced as 2023 Award Recipients by the Healthcare Businesswomen's Association

Retrieved on: 
Thursday, January 12, 2023
Disease, Associate, Optometry, Advisory board, Lilly, Woman of the Year, BIO, Biotechnology Innovation Organization, Infection, HOPE, JAG, National Society of Certified Healthcare Business Consultants, Healthcare Businesswomen's Association, Partnership, Mentorship, Novartis, Workplace, Johnson & Johnson, Cardiology, Woman, CAR, Lymphatic system, Patient, HBA, Workforce, Boston, Cancer, Allergan, Parity, AbbVie, Science, STAR, Alzheimer's disease, Female, Health, Management, Medicine, Pharmaceutical industry, Neuroscience

FAIRFIELD, N.J., Jan. 12, 2023 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) announces the 2023 Woman of the Year, Honorable Mentor, and STAR. Recognized for their outstanding contributions to healthcare and the advancement of women in the workplace, the honorees will be celebrated at HBA's 33rd annual Woman of the Year event on 16 May in New York City and virtually around the globe.

Key Points: 
  • FAIRFIELD, N.J., Jan. 12, 2023 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) announces the 2023 Woman of the Year, Honorable Mentor, and STAR.
  • Christi Shaw, Chief Executive Officer, Kite, a Gilead Company, was selected as the 2023 Woman of the Year.
  • The HBA Woman of the Year award honors a female senior executive whose accomplishments have resulted in significant contributions to the healthcare industry.
  • In addition to her commitment to the HBA, Liz has spent her career championing the use of data to improve healthcare.

EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting

Retrieved on: 
Thursday, February 2, 2023
Cardiovascular disease, CXCR4, Sarcoidosis, Lymphoma, Lausanne University Hospital, Lymphatic system, Muscle tissue, Cardiology, Internal medicine, Diagnosis, Myocarditis, Patient, Leukemia, Research, CHUV, ISS, Nuclear medicine, GMP, Pharmaceutical industry, Medical imaging, Medical device

The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting.

Key Points: 
  • The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting.
  • It is the first time that Eckert & Ziegler’s proprietary CXCR4-compound is used in an advanced clinical test in a non-cancer indication, opening the way for a broader use of PENTIXAFOR outside of oncology.
  • To investigate the potential of PENTIXAFOR the CHUV will recruit, on its own account, up to 60 patients in a so-called investigator initiated study (ISS).
  • PENTIXAFOR is being developed by Eckert & Ziegler’s subsidiary Pentixapharm GmbH primarily as a superiorly sensitive diagnostic for rare blood cancers, among them myelomas, lymphoma and leukaemia.

ASTCT to Present Distinguished Honors at the 2023 Tandem Meetings

Retrieved on: 
Tuesday, January 17, 2023
Pharmacist, National Cancer Institute, Bedside, Blood, NCI, ASCO, Lymphoma, Lymphatic system, Degenerative disease, Fred Hutchinson Cancer Research Center, Haematopoietic system, Nursing, FDA, Knowledge, Immune tolerance, ASH, Lecture, AACR, Tandem, Patient, Transplant, Society, GVHD, Doctor of Philosophy, Physician, Leukemia, Dentistry, MD, Bench

CHICAGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- American Society for Transplantation and Cellular Therapy (ASTCT) will present top awards to leaders in the field of transplantation and cellular therapy at the Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® on Saturday, Feb. 18 in Orlando, Florida.

Key Points: 
  • CHICAGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- American Society for Transplantation and Cellular Therapy (ASTCT) will present top awards to leaders in the field of transplantation and cellular therapy at the Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® on Saturday, Feb. 18 in Orlando, Florida.
  • Fred Appelbaum, MD will receive the 2023 ASTCT Lifetime Achievement Award.
  • Additional information about the 2023 award winners is available on the 2023 Tandem Meetings website .
  • Follow #Tandem23 for the latest updates on the 2023 Tandem Meetings.

Precision Laser in Easton, PA Upgrades Technology to the Asclepion PicoStar® Picosecond Laser Backed by Astanza

Retrieved on: 
Wednesday, January 11, 2023
Laser, Lymphatic system, Asclepeion, Pain, 3D printing

EASTON, Penn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Precision Laser , Easton, Pennsylvania’s leading aesthetic laser provider, has upgraded its nanosecond tattoo removal technology to the Asclepion PicoStar® picosecond laser, backed by Astanza.

Key Points: 
  • EASTON, Penn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Precision Laser , Easton, Pennsylvania’s leading aesthetic laser provider, has upgraded its nanosecond tattoo removal technology to the Asclepion PicoStar® picosecond laser, backed by Astanza.
  • Since its establishment in 2019, Precision Laser has become a household name in the greater Easton and Lehigh Valley area for advanced laser tattoo removal, laser hair removal, laser facials, pigmented lesion removal, and more.
  • The growing practice is excited to give clients the best treatments with its upgraded laser.
  • We couldn’t be more excited to bring this advanced picosecond technology to Easton.”
    The PicoStar ® laser combines quality and technology and is the most advanced picosecond laser for treating unwanted tattoos, permanent makeup, and more.

Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Retrieved on: 
Tuesday, January 10, 2023
Cell, Prostate cancer, Cancer, University, Lymphatic system, Multiple myeloma, Cyclophilin, Fatty liver disease, Hepatocellular carcinoma, Chronic liver disease, Protein, Ixazomib, Mouse, Carfilzomib, HEPA, Liver cancer, Artificial intelligence, Doctor of Philosophy, NASH, Pharmaceutical industry, Vaccine

The presentation, entitled “A New Strategy to Increase Proteotoxic Stress in Prostate Cancer,” highlighted a preclinical study which investigated the killing of cultured prostate cancer cells by rencofilstat in combination with a proteasome inhibitor, ixazomib.

Key Points: 
  • The presentation, entitled “A New Strategy to Increase Proteotoxic Stress in Prostate Cancer,” highlighted a preclinical study which investigated the killing of cultured prostate cancer cells by rencofilstat in combination with a proteasome inhibitor, ixazomib.
  • Proteosome inhibitors are a class of anti-cancer agents that are used for the treatment of multiple myeloma and other blood cancers.
  • The present study showed that rencofilstat could synergistically increase the proteotoxic stress and in vitro cancer killing properties of ixazomib.
  • In this preclinical study, rencofilstat and ixazomib were applied at low concentrations to several types of prostate cancer cell lines, and also to non-cancerous prostate cells.